Galectin-3 表达对接受铂类辅助化疗的 NSCLC 患者的预后意义。
Prognostic significance of galectin-3 expression in patients with resected NSCLC treated with platinum-based adjuvant chemotherapy.
机构信息
Department of Respiratory Medicine, School of Medicine, Kitasato University, Sagamihara, Japan.
Department of Pathology, School of Medicine, Kitasato University, Sagamihara, Japan.
出版信息
Thorac Cancer. 2021 May;12(10):1570-1578. doi: 10.1111/1759-7714.13945. Epub 2021 Apr 1.
BACKGROUND
Galectin-3 (GAL3), a protein encoded by the LGALS3 gene, plays diverse roles in cancer initiation, progression, and drug resistance. Accordingly, high GAL3 expression in tumor cells is associated with poor prognosis in non-small cell lung cancer (NSCLC). However, the prognostic impact of GAL3 expression on patients with resected NSCLC receiving platinum-based adjuvant chemotherapy (AC) remains unclear. This study aimed to determine the prognostic significance of GAL3 expression in NSCLC patients receiving platinum-based AC.
METHODS
The study included 111 patients with completely resected stages II and IIIA NSCLC who were receiving platinum-based AC. GAL3 expression in cancer cells was evaluated immunohistochemically according to H-score ("histo score), with a score of ≥170 considered as high expression. The correlation of GAL3 expression with clinicopathological characteristics and survival was subsequently evaluated.
RESULTS
In survival analysis, GAL3 expression was significantly associated with recurrence-free survival (RFS) and overall survival (OS). In multivariate analysis, GAL3 expression was an independent predictive factor of RFS rather than OS.
CONCLUSIONS
GAL3 expression is a reliable biomarker to predict the prognosis of completely resected NSCLC patients receiving platinum-based AC.
背景
半乳糖凝集素-3（GAL3）是由 LGALS3 基因编码的一种蛋白质，在癌症的发生、发展和耐药性中发挥着多种作用。因此，肿瘤细胞中高表达 GAL3 与非小细胞肺癌（NSCLC）的预后不良相关。然而，GAL3 表达对接受铂类辅助化疗（AC）的 NSCLC 患者的预后影响尚不清楚。本研究旨在确定 GAL3 表达对接受铂类 AC 的 NSCLC 患者的预后意义。
方法
该研究纳入了 111 例接受铂类 AC 的完全切除的 II 期和 IIIA 期 NSCLC 患者。根据 H 评分（“组织评分”），通过免疫组织化学评估癌细胞中 GAL3 的表达，将≥170 分定义为高表达。随后评估 GAL3 表达与临床病理特征和生存的相关性。
结果
在生存分析中，GAL3 表达与无复发生存（RFS）和总生存（OS）显著相关。多变量分析显示，GAL3 表达是 RFS 的独立预测因素，而不是 OS。
结论
GAL3 表达是预测接受铂类 AC 的完全切除 NSCLC 患者预后的可靠生物标志物。
Zotero 插件